| abstract |
An ophthalmic treatment composition, such as a polymer drug delivery system, contains a treatment component that includes a sirtuin activator (eg, resveratrol) that treats the ocular condition when delivered to the posterior eye segment of a mammal. Also disclosed are methods of making and using the compositions. |